Cartesian Therapeutics (RNAC) News Today $19.34 -0.28 (-1.40%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Cartesian Therapeutics to Participate in Upcoming Investor ConferencesFebruary 18 at 7:00 AM | globenewswire.comBrokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86February 14, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for RNAC FY2024 Earnings?February 12, 2025 | americanbankingnews.comFY2024 Earnings Forecast for RNAC Issued By Leerink PartnrsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Cartesian Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will postFebruary 10, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from AnalystsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has earned an average rating of "Moderate Buy" from the ten brokerages that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation toFebruary 9, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for RNAC FY2029 Earnings?Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Cartesian Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will poFebruary 7, 2025 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsFebruary 6, 2025 | globenewswire.comPromising Developments and Strategic Expansion Bolster Buy Rating for Cartesian TherapeuticsJanuary 29, 2025 | markets.businessinsider.comStrong Outlook for Cartesian Therapeutics: FDA SPA Agreement and Positive Phase 2b Results Boost Confidence in Descartes-08January 28, 2025 | markets.businessinsider.comBuy Rating for Cartesian Therapeutics: Promising Phase 3 Prospects for Descartes-08 in Treating Myasthenia GravisJanuary 28, 2025 | markets.businessinsider.comCartesian Therapeutics (NASDAQ:RNAC) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $45.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday.January 28, 2025 | marketbeat.comCartesian Therapeutics announces FDA SPA agreement for Phase 3 AURORA trialJanuary 27, 2025 | markets.businessinsider.comNeedham & Company LLC Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)Needham & Company LLC reissued a "buy" rating and set a $41.00 price target on shares of Cartesian Therapeutics in a research note on Monday.January 27, 2025 | marketbeat.comCartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia GravisJanuary 27, 2025 | globenewswire.comCartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA TherapiesJanuary 17, 2025 | seekingalpha.comPromising Developments and Strategic Milestones Drive Buy Rating for Cartesian TherapeuticsJanuary 15, 2025 | markets.businessinsider.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten brokerages that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and eight have issuedJanuary 15, 2025 | marketbeat.comCartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune DiseasesJanuary 13, 2025 | markets.businessinsider.comCartesian Therapeutics (NASDAQ:RNAC) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $41.00 price target on shares of Cartesian Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comCartesian Therapeutics announces employment inducement grantsJanuary 8, 2025 | markets.businessinsider.comMilos Miljkovic Sells 932 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) StockJanuary 8, 2025 | insidertrades.comMilos Miljkovic Sells 932 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) StockCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) insider Milos Miljkovic sold 932 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $16.72, for a total transaction of $15,583.04. Following the transaction, the insider now directly owns 36,341 shares in the company, valued at approximately $607,621.52. This represents a 2.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.January 7, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Insider Milos Miljkovic Sells 948 SharesCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) insider Milos Miljkovic sold 948 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $16.83, for a total value of $15,954.84. Following the sale, the insider now owns 35,393 shares in the company, valued at approximately $595,664.19. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 7, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells $40,412.24 in StockCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CTO Metin Kurtoglu sold 2,417 shares of the company's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $16.72, for a total transaction of $40,412.24. Following the transaction, the chief technology officer now owns 64,716 shares of the company's stock, valued at $1,082,051.52. This represents a 3.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.January 7, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 2,458 SharesCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CTO Metin Kurtoglu sold 2,458 shares of Cartesian Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $16.83, for a total value of $41,368.14. Following the completion of the transaction, the chief technology officer now directly owns 62,258 shares of the company's stock, valued at $1,047,802.14. This represents a 3.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.January 7, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) CFO Sells $66,227.92 in StockCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CFO Blaine Davis sold 3,961 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $16.72, for a total value of $66,227.92. Following the completion of the transaction, the chief financial officer now directly owns 98,839 shares of the company's stock, valued at approximately $1,652,588.08. The trade was a 3.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.January 7, 2025 | marketbeat.comInsider Selling: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CFO Sells 4,028 Shares of StockCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CFO Blaine Davis sold 4,028 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $16.83, for a total value of $67,791.24. Following the completion of the transaction, the chief financial officer now owns 94,811 shares of the company's stock, valued at $1,595,669.13. The trade was a 4.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.January 7, 2025 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsJanuary 7, 2025 | globenewswire.comCartesian Therapeutics (RNAC) Has a New Rating from BTIGDecember 30, 2024 | markets.businessinsider.comCartesian Therapeutics (NASDAQ:RNAC) Stock Price Up 7.2% - Time to Buy?Cartesian Therapeutics (NASDAQ:RNAC) Trading Up 7.2% - Here's What HappenedDecember 26, 2024 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by BrokeragesCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have given a buy ratingDecember 21, 2024 | marketbeat.comCartesian Therapeutics initiated with a Buy at BTIGDecember 20, 2024 | markets.businessinsider.comBTIG Initiates Coverage of Cartesian Therapeutics (RNAC) with Buy RecommendationDecember 20, 2024 | msn.comBTIG Research Begins Coverage on Cartesian Therapeutics (NASDAQ:RNAC)BTIG Research assumed coverage on shares of Cartesian Therapeutics in a report on Thursday. They issued a "buy" rating and a $42.00 price target on the stock.December 19, 2024 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsDecember 18, 2024 | globenewswire.comFmr LLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Fmr LLC boosted its holdings in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 458.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,851,830 shares of the company's stock after pDecember 8, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Cartesian Therapeutics (RNAC) and Terns Pharmaceuticals (TERN)December 6, 2024 | markets.businessinsider.comCartesian shares updated Phase IIb Descartes-08 data and announces Phase III trial plansDecember 6, 2024 | msn.comCantor Fitzgerald Predicts RNAC FY2024 EarningsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Cartesian Therapeutics in a report issued on Monday, December 2nd. Cantor Fitzgerald analyst K. Kluska forecasts that the company willDecember 4, 2024 | marketbeat.comCartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 TrialDecember 3, 2024 | globenewswire.comGreat Point Partners LLC Makes New Investment in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Great Point Partners LLC purchased a new position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 200,000 shares of the company's stock,November 27, 2024 | marketbeat.comPromising Developments and Strategic Positioning Drive Buy Rating for Cartesian TherapeuticsNovember 25, 2024 | markets.businessinsider.comCartesian Therapeutics (NASDAQ:RNAC) Given Buy Rating at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $41.00 price objective on shares of Cartesian Therapeutics in a report on Monday.November 25, 2024 | marketbeat.comCartesian therapeutics CTO sells $649,029 in stockNovember 23, 2024 | investing.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 32,789 SharesNovember 22, 2024 | insidertrades.comTimothy Springer Bought 4.9% More Shares In Cartesian TherapeuticsNovember 22, 2024 | finance.yahoo.comCartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease SummitNovember 21, 2024 | globenewswire.comCartesian Therapeutics executive sells $875,042 in stockNovember 20, 2024 | investing.comCartesian Therapeutics (NASDAQ:RNAC) Shares Gap Up - What's Next?Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap Up - What's Next?November 19, 2024 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells 25,900 SharesNovember 19, 2024 | insidertrades.com Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address RNAC Media Mentions By Week RNAC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNAC News Sentiment▼0.000.60▲Average Medical News Sentiment RNAC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNAC Articles This Week▼13▲RNAC Articles Average Week Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TARS News Today JANX News Today AGIO News Today NAMS News Today IDYA News Today SDGR News Today TVTX News Today BLTE News Today VERA News Today IOVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNAC) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
